Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01833 PA GOODDOCTOR
RTNominal down11.800 -0.020 (-0.169%)
Research Report

07/01/2020 17:03

{I-bank focus}Citi lifts PA Good Doctor (01833) to HK$75

[ET Net News Agency, 7 January 2020] Citi Research lifted its target price for Ping An
Healthcare and Technology (PAGD)(01833) to HK$75 from HK$60 and maintained its "buy"
rating.
The research house said PAGD, as the largest internet hospital platform in China, has
the potential to play a key role in reforming the healthcare system by (1) allocating
medical resources to rural patients in need, (2) improving diagnostic/prescription
efficiencies, (3) unleashing idle medical resources in public hospitals, (4) promoting Rx
outsourcing from public hospitals, and (5) increasing in the long term
commercial-insurance participation in China.
Citi raised its revenues for 2019/20/21 to reflect the policy tailwinds from the
reimbursement of online medical consultation and lower SG&A expenses on saved promotion
activities and improved efficiency. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.